Phase I–II trial designs: how early should efficacy guide the dose recommendation process?
Phase I–II trial designs: how early should efficacy guide the dose recommendation process?. Paoletti, X; Postel-Vinay, S. Annals of Oncology. 2018; 540-541: p.540-541. doi:10.1093/annonc/mdy044
Oncostat